Table 5 Sixteen oncolytic adenoviruses used in phase I–II trials that have been completed or recruiting (Mar-2020 clinicaltrials.org).
First posted | Last update | Oncolytic adenovirus (transgene) | Study title(s) | Indication(s) | NCT# identifier |
|---|---|---|---|---|---|
2012 | 2019 | ONCOS-102a (GMCSF) | Completed: ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers Recruiting: (1) A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade (2) A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer | Solid tumors, melanoma, and prostate cancer | NCT03003676, NCT03514836 |
2012 | 2015 | Delta-24-rgd | Completed: Safety Study of Replication-competent Adenovirus (Delta-24-rgd) in Patients With Recurrent Glioblastoma | Glioblastoma | NCT01582516 |
2013 | 2020 | DNX-2401b | Completed: (1) Oncolytic Adenovirus, DNX-2401, for Naive Diffuse Intrinsic Pontine Gliomas (2) DNX-2401 With Interferon Gamma (IFN-γ) for Recurrent Glioblastoma or Gliosarcoma Brain Tumors (TARGET-I) (3) Virus DNX2401 and Temozolomide in Recurrent Glioblastoma (D24GBM) Recruiting: Oncolytic Adenovirus DNX-2401 in Treating Patients With Recurrent High-Grade Glioma | Gliomas | NCT03178032, NCT02197169, NCT01956734, NCT03896568 |
2013 | 2016 | CELYVIR | Completed: Safety and Efficacy of Repeated Infusion of CELYVIR in Children and Adults With Metastatic and Refractory Tumors. | Solid tumors | NCT01844661 |
2013 | 2017 | ICOVIR-5 | Completed: Phase I Endovenous Administration of Oncolytic Adenovirus ICOVIR-5 in Patients With Advanced or Metastatic Melanoma | Melanoma | NCT01864759 |
2014 | 2019 | VCN-01 (PH20 hyaluronidase) | Completed: A phase I Dose Escalation Study of Intratumoral VCN-01 Injections With Gemcitabine and Abraxane in Patients With Advanced Pancreatic Cancer Recruiting: Safety, Tolerability, and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma | Pancreatic cancer and head and neck | NCT03284268, NCT03799744 |
2014 | 2020 | ColoAd1c | Completed: Mechanism of Action Trial of ColoAd1 (MOA) Recruiting: Chemoradiation With Enadenotucirev as a Radiosensitiser in Locally Advanced Rectal Cancer (CEDAR) | Colon, non-small cell lung, bladder, and renal cell | NCT02053220 |
2015 | 2019 | CG0070 (GMCSF) | Completed: Safety and Efficacy of CG0070 Oncolytic Virus Regimen for High Grade NMIBC After BCG Failure (BOND2) | Superficial bladder cancer | NCT02365818 |
2020 | 2020 | TILT-123d (TNFalpha and IL-2) | Recruiting: TNFalpha and Interleukin 2 Coding Oncolytic Adenovirus TILT-123 During TIL Treatment of Advanced Melanoma | Melanoma | NCT04217473 |
2016 | 2020 | LOAd703 (CD40L and 41BBL) | Recruiting: (1) Trial Investigating an Immunostimulatory Oncolytic Adenovirus for Cancer (2) LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer (3) A Phase I/II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma | Pancreatic, ovarian, biliary, colorectal, and melanoma | NCT03225989, NCT02705196, NCT04123470 |
2019 | 2020 | ORCA-010 | Recruiting: First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients. | Prostate cancer | NCT04097002 |
2017 | 2017 | Ad5-yCD/mutTKSR39rep-hIL12 (IL-12) | Recruiting: Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer | Pancreatic cancer | NCT03281382 |
2017 | 2019 | NSC-CRAd-Survivin-pk7 | Recruiting: Neural Stem Cell Based Virotherapy of Newly Diagnosed Malignant Glioma (neural stem cells loaded with NSC-CRAd-Survivin-pk7) | Glioma | NCT03072134 |
2019 | 2020 | NG-641 (CXCL9/CXCL10/IFNα) | Recruiting: First in Human Study With NG-641, an Oncolytic Transgene Expressing Adenoviral Vector FAP-TAc antibody together with an immune enhancer module (CXCL9/CXCL10/IFNα). | Epithelial tumors | NCT04053283 |
2016 | 2019 | ADV/HSV-tk (HSV-tk) | Recruiting: SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC (STOMP) | Breast and lung | NCT03004183 |
2019 | 2020 | NG-350A (anti-CD40 ab) | Recruiting: First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody) (FORTITUDE) | Epithelial tumors | NCT03852511 |